Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 09/28 10:14:59 pm
78.97 USD   -0.35%
09/27 GILEAD SCIENCES : and the World Health Organization Announce Five-Ye..
09/27 NASDAQ 100 MOVE : Gild, nclh
09/22 ABZENA : Says Gilead Halts Ulcerative Colitis Trials For GS-5745
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
09/27 GILEAD SCIENCES : and the World Health Organization Announce Five-Year Visceral ..
09/27 NASDAQ 100 MOVERS : Gild, nclh
09/22 ABZENA : Says Gilead Halts Ulcerative Colitis Trials For GS-5745
09/21 GILEAD SCIENCES : Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerat..
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 GILEAD SCIENCES INC : Entry into a Material Definitive Agreement, Creation of a ..
09/20 STOCKS HIGHLIGHTS : Gilead Sciences, Inc. Wellcare Health Plans, Inc.
09/16 GILEAD SCIENCES : Prices $5 Billion of Senior Unsecured Notes
09/15 GILEAD SCIENCES : to Present at Three Upcoming Investor Conferences in September
09/14 GILEAD SCIENCES, INC. : ex-dividend day
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/28 VALEANT : Is Bankruptcy Possible?
09/27 My 85 Stock Portfolio Evaluation Of Want To Buy Prices And Yields For Purchas..
09/27 Allergan Validates Gilead Sciences NASH Pipeline
09/27 Gilead cut at Leerink, shares lower premarket
09/27 5 Great Ways To Potentially Earn Fantastic Yield On Gilead's Crazy Cheap Shar..
Advertisement
Financials ($)
Sales 2016 30 469 M
EBIT 2016 20 160 M
Net income 2016 14 539 M
Debt 2016 5 504 M
Yield 2016 2,34%
P/E ratio 2016 7,46
P/E ratio 2017 7,14
EV / Sales 2016 3,61x
EV / Sales 2017 3,58x
Capitalization 104 583 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 105 $
Spread / Average Target 33%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-21.68%106 391
AMGEN, INC.5.73%129 863
CELGENE CORPORATION-10.32%82 402
REGENERON PHARMACEUTIC..-22.37%42 552
VERTEX PHARMACEUTICALS..-29.17%21 876
ACTELION LTD19.91%18 591
More Results